Zacks Investment Research lowered shares of Inflarx (NASDAQ:IFRX) from a hold rating to a sell rating in a research note released on Tuesday morning.
According to Zacks, “InflaRx N.V. is a clinical-stage biopharmaceutical company. It focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. InflaRx N.V. is based in Germany. “
IFRX has been the topic of several other research reports. BMO Capital Markets initiated coverage on shares of Inflarx in a report on Friday, July 13th. They issued an outperform rating and a $45.00 price target on the stock. SunTrust Banks initiated coverage on shares of Inflarx in a report on Thursday, June 28th. They issued a buy rating and a $55.00 price target on the stock. Finally, Raymond James initiated coverage on shares of Inflarx in a report on Thursday, June 28th. They issued an outperform rating and a $44.00 price target on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. Inflarx presently has an average rating of Buy and a consensus price target of $42.67.
Inflarx (NASDAQ:IFRX) last announced its quarterly earnings results on Thursday, August 9th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.36) by $0.24. As a group, sell-side analysts forecast that Inflarx will post -1.43 EPS for the current year.
Several institutional investors and hedge funds have recently bought and sold shares of IFRX. Schwab Charles Investment Management Inc. bought a new stake in shares of Inflarx in the 1st quarter worth about $367,000. Northern Trust Corp bought a new stake in shares of Inflarx in the 1st quarter worth about $228,000. Barclays PLC bought a new stake in shares of Inflarx in the 1st quarter worth about $144,000. Birchview Capital LP bought a new stake in shares of Inflarx in the 2nd quarter worth about $516,000. Finally, Citadel Advisors LLC grew its holdings in shares of Inflarx by 42.1% in the 2nd quarter. Citadel Advisors LLC now owns 190,180 shares of the company’s stock worth $6,133,000 after purchasing an additional 56,309 shares during the last quarter. 54.80% of the stock is currently owned by institutional investors and hedge funds.
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.
Featured Story: Price to Earnings Ratio (PE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inflarx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inflarx and related companies with MarketBeat.com's FREE daily email newsletter.